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continues as we await state approval of 
our Certificate of Need (CON) for a 
52-bed skilled nursing facility. Plans 
to renovate our GI Lab have been 
cleared at the state level, and 
remodeling is anticipated to begin in 
the near future. Also, 7C has been 
remodeled and is now our Nephrology 
Unit. At 17th & Chew, 5T and 4T 
have closed, while 4S has become a 
36-bed patient care unit. 
Several important searches continue. 
The Chief of Surgery search continues, 
and we all hope for positive news 
shortly. A search is well underway for 
the Chief Operating Officer. Several 
excellent candidates have been 
interviewed, and the committee will be 
meeting again within the next several 
weeks to discuss these candidates. 
Elliot Sussman, M.D., has asked me to 
chair a committee to search for the 
Chief of Clinical Services. Our first 
meeting will be held within the next 
few weeks, and, hopefully, we will 
have candidates to interview shortly 
thereafter. 
As a reminder, the Physician 
Assistance Program is continuing its 
confidential professional counseling 
services to active members of the 
Medical Staff and their dependents. 
This program offers physicians and 
families counseling services for a wide 
range of personal problems, and is of a 
strictly confidential nature and easy to 
use. The number is 433-8550 or 1-
800-327-8878, requiring only the 
identification as a. member of Lehigh 
Valley Hospital medical staff or a 
family member, and ask to speak to the 
Program Manager, Oliver Neith. 
Also, for the past two years, our 
Physician Well-Being group has met 
every other week from 6 to 7:30p.m. 
All meetings are held in the 
Conference Dining Room at Cedar 
Crest & I-78. If anyone has questions 
or needs information, please contact 
John Turoczi, EdD, Group Facilitator, 
at (610) 481-9161. 
Finally, on a sad note, we all extend 
our sympathies to Russ Rentler for the 
recent loss of his wife, Susan. Anyone 
wishing to contribute to a fund to help 
Russ obtain the services of a nanny for 
his young children may contact the 
Medical Staff Office at 402-8900. 
Best wishes to all, 
A. Candio 
dent, Medical Staff 
Laboratory Update 
Handy Reference 
Health Network Laboratories is structured to assure that most 
technical or logistical questions can be handled by the supervisor of the division in 
question. However, if you ever have a question that requires further clarification, 
a technical director is available to assist you. 
Listed below is a handy reference of those individuals technically responsible for 
the various divisions of the laboratory. 
Division Technical Director Supervisor 
Microbiology/ David G. Beckwith, Ph.D. Georgia Colasante 
Virology 402-8157 402-8196 
Immunology David G. Beckwith, Ph.D. Gale Fritch 
Flow Cytometry 402-8157 402-2845 
Gerald E. Clement, Ph.D. 
402-8156 or 402-2534 
HLA Laboratory Bala B. Carver, M.D. Marjorie Williams 
402-8142 or 402-2571 402-8016 
Blood Bank Bala B. Carver, M.D. Kathleen Mundt 
402-8142 or 402-2571 402-8180 
Hematology David Prager, M.D. Dolores Benner 
Coagulation 433-6691 402-8177 
Toxicology Gerald E. Clement, Ph.D. Joann Sell 
Endocrinology 402-8156 or 402-2534 402-2578 
Chemistry Gerald E. Clement, Ph.D. Jan Gushen 
402-8156 or 402-2534 402-8043 
Cytology William Dupree, M.D. Linda Pflueger 
402-2551 402-2835 
General laboratory concerns can be handled by David G. Beckwith, Ph.D., 
Administrator and Clinical Director, at 402-8150 or John J. Shane, M.D., 
Chairman, Department of Pathology, at 402-8152. 
Continued on Page 3 
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Laboratory Newsletter 
In an effort to provide you with timely 
infonnation regarding laboratory-
related issues, beginning this month, 
Medical Sttif/ Progress Notes will 
regularly include a brief newsletter 
published by Health Network 
Consolidation Moves 
On March 2, the 4S Nephrology unit 
began transitioning to the newly 
renovated 7C wing at Cedar Crest & 
1-78. The new telephone number for 
the unit is 402-1900. Simultaneously, 
the 5T medical/surgical unit was 
closed, and the 4T occupancy increased 
to 36 patients. 
With 4T remaining as the only 
medical/surgical unit, medical patient 
admissions will need to be directed to 
the appropriate sites. All elective 
medical admissions, with the exception 
of GIMs C & D and patients of Drs. 
Mishriki, Kelly, Levy, and Karess, 
should be directed to Cedar Crest & 
1-78. 
A recent violation received from the 
Bureau of Quality Assurance included 
the fact that alterations on the records 
are not corrected appropriately. Please 
be aware that the correct method for 
correcting errors on the record is to 
draw a line through the incorrect entry, 
write "error," date and initial. 
Laboratories. This month's newsletter 
can be found on pages 25-27. If you 
have any questions or ideas for future 
topics, please contact Gerald E. 
Clement, Ph.D., Director, Chemistry, 
at 402-2534. 
Urgent and emergent medical 
admissions should be directed to the 
emergency department at the facility 
where inpatient medical/surgical beds 
are available. Facility medical/surgical 
bed availability information is 
continuously available by calling 
402-1875. 
Psychiatric, obstetric, pediatric, and 
surgical patient services will continue 
at present at 17th & Chew. 
If you have any questions or concerns, 
please contact Mary Agnes Fox, 
Administrator, Patient Care Services, 
at 402-2285, or Kate Quinn O'Hara, 
Administrator, Patient Care Services, 
at 402-8210. 
Currently, guidelines have not been 
established whereby Attestations and 
Transcription reports can be signed 
electronically. Attestations must bear 
the original signature of the physician 
who has treated the patient. 
Attestations and Transcription reports 
which have on-line verification will not 
be acceptable and physicians will be 
requested to sign a paper copy. 
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Intrarectal Ultrasonography Now Available 
The John and Dorothy Morgan Cancer 
Center is pleased to announce the 
availability of a new modality for the 
evaluation of anorectal disorders. 
Intrarectal ultrasonop-apby is used 
pre-operatively to determine the depth 
of penetration of rectal tumors and to 
evaluate the possible involvement of 
regional lymph nodes. In addition, 
intrarectal ultrasonography is valuable 
for evaluating recurrent pelvic disease. 
Lymph node biopsy through the 
ultrasound probe is feasible. 
This technique may also be applied to 
the evaluation of benign diseases of the 
anorectum. It can be used to evaluate 
the sphincter mechanism in patients 
with incontinence, particularly in post-
partum women. For complex anorectal 
problems, including fistula-in-ano and 
intersphincteric abscesses, the 
New Liquid Oxygen System 
On Monday, March 28, the 
Respiratory Services Department will 
implement a new oxygen system which 
will be used in the transport and 
transfer of patients at the Cedar Crest 
& 1-78 site only. 
The new oxygen system utilizes liquid 
0 2 portables (LOX). This system 
contains more oxygen under less 
pressure than the traditional ~ 
cylinder. In addition, it has a self-
contained regulator and flow meter, 
and the LOX portable is refillable. 
CAUTION-- As this is a liquid, the 
LOX portables must remain upright at 
aU times. 
application of this device has been 
shown to be valuable. 
With the availability of this procedure, 
in conjunction with other diagnostic 
tests, one can tailor the operative 
management to the extent of the 
disease. Thus, radical surgery with the 
creation of a permanent stoma may be 
avoided with the possibility of local 
excision affording the same cure. 
The intrarectal ultrasound is located in 
the G.I. Laboratory at Cedar Crest & 
1-78. For more information, please 
contact lndru T. Khubchandani, M.D., 
Colon/Rectal Unit Director, John and 
Dorothy Morgan Cancer Center, at 
402-0500. To schedule a patient for 
this procedure, please contact the G.I. 
Laboratory at 402-8850. 
If you have any questions or need 
further information, please contact 
Wally Smith, Respiratory Equipment 




New Area Code Change Affects Cellular Telephones 
As you know, in January, a significant 
portion of Pennsylvania received a new 
area code. In addition to home and 
office telephones, the area code change 
has also affected cellular telephones. 
Cellular telephones mst be physically 
programmed with the new 610 area 
code. Depending on the type of 
cellular telephone you have, 
reprogramming may take only a few 
minutes. Failure to have this done by 
December 31, 1994, will result in the 
loss of service to your cellular 
telephone. 
As a convenience to physician and 
employee users on the HealthPage 
Plan, the CellularOne reprogramming 
team will visit both sites of Lehigh 
Valley Hospital on the following dates 
to re-program your cellular telephones 
at your convenience and at no charge: 
March 21-25 
8:30a.m. to 4:30p.m. 
March 28-April 1 
8:30 a.m. to 4:30 p.m. 
At Cedar Crest & 1-78, the 
CellularOne van will be stationed in or 
near the Physicians' Parking Lot. At 
17th & Chew, the CellularOne van will 
be stationed in the Visitors' Parking 
Lot somewhere between First Fidelity 
Bank and the parking deck of the 
Fairgrounds Medical Center. If you are 
not available during any of these times, 
please call the reprogramming team at 
390-6113 to schedule an alternate time. 
Research Advisory Committee - Request for Proposals 
The Research Advisory Committee 
(RAC) meets bi-monthly to review 
clinical/epidemiological research 
proposals (requests for funding) 
submitted by the medical and 
professional staff of Lehigh Valley 
Hospital. All proposals must be 
submitted to the Research Department 
for review three weeks before the next 
scheduled RAC meeting. The next 
meeting of the RAC is April20. All 
proposals submitted by April 1 will be 
reviewed by the Research Department 
before being placed on the RAC 
agenda. 
For more information and/or proposal 
guidelines, contact James F. Reed ill, 




New acquisitions to the Health Sciences 
Library at Cedar Crest & 1-78 include: 
• Baum. Marketing Your Clinical Practice: 
Ethically, Effectively, Economically. Aspen 
Publishers, 1992. 
• Harrison. Harrison's Principles of 
Internal Medicine. 13th ed. McGraw Hill, 
1994. 
• The Of(icial ABMS Diretory of Board 
Certiraecl Medical Specialists. 26th ed. Reed 
Reference Publishing, 1993. 
New acquisitions at 17th & Chew include: 
• Avery. Neonatology. 4th ed. J.B. 
Lippincott, 1994. 
• Creasy. Maternal Fetal Medicine. 3rd ed. 
W.B. Saunders, 1994. 
• Jackson. Primary Care of tbe Child with 
a Chronic Condition. Mosby-Year Book, 
1992. 
+ Physicians routinely receive 
advertisements for new_ books. Please 
forward recommendations for new library 
purchases to the Library Director at Cedar 
Crest & 1-78. Your assistance in helping 
to maintain a current/relevant book 
collection is appreciated. 
+ The library utilizes Rittenhouse as its 
book jobber. As a convenience, 
physicians may also order medical books 
for personal use through Rittenhouse. For 
a book order form· and instructions or for 
more information, call the Health Sciences 
Library at 402-8410 (Cedar Crest & 1-78) 
or 402-2263 (17th & Chew). 
LV AHEC Annual Category 1 CME Letter 
Accreditation for Continuing Medical 
Education (CME) in the Lehigh Valley is 
undertaken by the Lehigh Valley Area 
Health Education Center (LV AHEC). 
LV AHEC accredits programs for Lehigh 
Valley Hospital, Sacred Heart Hospital, 
Quakertown Community Hospital, Easton 
Hospital, St. Luke's Hospital, Muhlenberg 
Hospital Center, Carbon County Medical 
Society, and Allentown Osteopathic 
Medical Center (for allopathic accredited 
programs). 
Each March, LV AHEC compiles and 
mails a letter to all physicians listing the 
programs attended at its member 
institutions during the past calendar year. 
This letter serves as documentation for 
reporting to the American Medical 
Association Physician's Recognition Award 
and for documenting CME credits to your 
insurance carrier. 
Shortly, every Lehigh Valley Hospital 
physician who (a) attended programs 
approved for CME Category 1 credit, and 
(b) had the program director report 
attendance to LV AHEC, should receive 
their letter. This will be your only 
documentation. There is a fee for 
replacement letters. 
Category 2 credit may be used for part of 
the Physician's Recognition Award; 
however, each physician must keep records 
of their own Category 2 CME. LV AHEC 
does not keep Category 2 attendance 
records. 
If you wish to apply for the American 
Medical Association Physician's 
Recognition Award, contact the American 




Physician Assistance Program 
25 Reasons to Take Advantage of the Physician Assistance Program 
1. Emotional and personality 
conflicts on the job. 
2. Money management. 
3. Depression. 
4. An adolescent who is using 
drugs or alcohol. 
5. Emotional support in deciding 
about appropriate care for 
elderly patients. 
6. A child who has a behavioral 
problem at home or at school. 
7. Chronic anxiety. 
8. Threatened violence or when 
you are the victim of violence. 
9. Feelings of being overwhelmed. 
10. Learning to be less passive and 
more assertive. 
11. Clarifying important life 
decisions. 
12. Eating disorders. 
13. Grieving the loss of loved ones. 
14. Creatively managing stress. 
15. Feelings of loneliness. 
16. Recognizing a drinking 
problem. 
17. Resources for marital 
counseling. 
18. Drug dependency or addiction 
problems. 
19. Gambling problems. 
20. A change in your energy level. 
21. Resources to call upon when 
living with an alcoholic. 
22. Working through a serious 
financial problem. 
23. Facing serious physical illness. 
24. If you are a recovering 
alcoholic and want help. 
25. Readjusting to a divorce or 
separation. 
For assistance with problems like 
these, contact The Counseling 
Program's office at (610) 433-8550 or 
800-327-8878, identify yourself ONLY 
as a member of the Lehigh Valley 
Hospital's Medical Staff (or a family 
member) and ask to speak to the 
Program Manager, Oliver Neith. 
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Legal Briefings 
A recent article published for attorneys who 
represent plaintiffs in medical malpractice 
cases offered the following advice. 
The high failure rate of claims against health 
care providers that are tried to a verdict can 
best be explained by the failure to properly 
screen a malpractice case prior to accepting 
the referral and pursuing the case. This is 
partially accounted for by the tendency of 
lawyers to "dabble" in medical malpractice 
and, therefore, fail to recognize the 
subtleties of what may appear to be 
negligence at first blush, but actually is an 
acceptable complication of a procedure or an 
adverse outcome that occurred without 
negligent conduct. Another factor is the 
availability of medical experts who will 
suggest to the plaintiff attorney that 
malpractice has, in fact, occurred. Contrary 
to popular opinion, the number of "hired 
guns" is actually minimal and the majority of 
these experts are physicians who do not 
specialize in medical malpractice testimony. 
An attorney who decides to pursue these 
cases should understand that the jury system 
is conservative in general, and highly 
conservative in medical negligence. Many 
people called for jury duty are health care 
patients who like and need their doctors. 
They do not want to believe that physicians 
and hospitals in the community do not render 
quality care. They have also seen and heard 
the media reports that physicians do not 
deliver babies anymore and that malpractice 
judgments significantly drive up health care 
costs. The latter statement may not be an 
accurate statement, but is certainly believed 
widely. 
It is also important for the plaintiff's 
attorney to understand that the legal "killer" 
is causation. The causation issue is 
invariably dispositive in cases involving 
misdiagnosis. In such cases, the defendant's 
failure to make a proper diagnosis is always 
evident, retrospectively. The only standard-
of-care issue is whether the defendant failed 
to make a proper differential diagnosis. But 
the real issue in diagnosis cases is causation. 
This is the litmus test on which the claim 
must be challenged repeatedly at the outset. 
Consider these examples: 
• A 54 year-old woman is diagnosed with 
cancer of the left breast. During surgery, 
the doctor discovers two tumors; 15 lymph 
nodes out of 24 test positive for cancer. The 
disease is categorized as Stage ll. 
The patient had felt one of the tumors 12 
months earlier, a fact documented in the 
examining physician's records. He told her 
not to worry in view of the fact that a 
screening mammogram conducted six months 
before had been normal. 
Sure sounds like clear negligence. Now 
consider this - even if the cancer diagnosis 
had been made 12 months earlier, the cancer 
still would have been categorized as Stage n. 
• A 25 year-old woman with a fever and a 
heart murmur is seen by her attending 
physician. Instead of being admitted to the 
hospital for high-dose intravenous 
antibiotics, she is given erythromycin as an 
outpatient. After two weeks, her symptoms 
have worsened, and she is admitted to the 
hospital, where she receives intravenous 
antibiotics for bacterial endocarditis. 
However, her aortic valve is seriously 
damaged and must be replaced. 
This case sounds solid. But consider that the 
most common complication of bacterial 
endocarditis, even when diagnosed early and 
treated vigorously, is destruction of the 
aortic valve. Valve replacement in this case 
would have been likely even if the woman 
had been admitted to the hospital 
immediately. 
If you have any questions regarding this 
article or any other legal issues, please 
contact the Department of Legal 





Enteral Formulary Revised 
The Enteral Formulary has been 
revised with the following changes 
being implemented this month. 
Replete with Fiber has been added to 
the Enteral Formulary. Promote has 
been added and will replace Nitrolan. 
Vivonex Plus has been added and will 
replace Vivonex TEN. NutriHep has 
been added and will replace Travasorb 
Hepatic. 
Description of New Products 
Replete with Fiber - A liquid, high 
protein, isotonic formula with 14 gms. 
fiber/liter - 1.0 cal/cc and 63 gms. 
protein per liter. 
Congratulations! 
George A. Arangio, M.D., orthopedic 
surgeon, has been reappointed as 
visiting research scientist in the 
Institute for Biomedical Engineering 
and Mathematical Biology. His current 
research and education projects include 
long term evaluation of iliotibial band 
replacement for the anterior cruciate 
deficient knee and the mathematical 
modeling of the foot and ankle in 
normal and injured states. Dr. 
Arangio collaborates with Professor 
Eric Salathe, Ph.D., graduate and 
undergraduate students on the above 
research projects. 
David G. Beckwith, Ph.D., 
Administrator and Clinical Director 
' Health Network Laboratories, was re-
elected Chairman of the Pennsylvania 
Promote- A liquid, high protein 
isotonic formula with 1. 0 call cc and 62 
gms. protein per liter. 
NutriHep- A liquid, high calorie 
formula for liver disease with an amino 
acid composition high in branched 
chain amino acids and low in aromatic 
amino acids. 1.5 callcc with 40 gms. 
protein per liter. 
Vivonex Plus - An elemental formula 
containing 100% free amino acids with 
10 gms. of free glutamine/liter. 1.0 
callcc and 45 gms. protein per liter. 
A new Enteral Formulary reference 
card (purple) is available from Clinical 
Nutrition Seivices. For a copy of the 
new reference card or for more 
information, contact Clinical Nutrition 
Services at 402-8313 or 402-8378. 
lnV Planning Council and Chairman 
of the Bethlehem Board of Health. 
Ross N. Futerfas, M.D., 
pulmonologist, was recently notified by 
the American Board of Internal 
Medicine that he successfully passed 
the Critical Care Medicine 
Examination and is now certified as a 
Diplomate in Critical Care Medicine. 
Thomas D. Meade, M.D., orthopedic 
surgeon, was recently certified as a 
team physician by the American 
College of Sports Medicine. Dr. 
Meade serves as the orthopedic team 
surgeon for Muhlenberg College, 
Parkland High School, and Whitehall 
High School. Dr. Meade is also the 
orthopedic consultant to Cedar Crest 
College, Emmaus High School, and 12 
additional area high schools. 
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Publications, Papers and Presentations 
Alan B. Leahey, M.D., 
ophthalmologist, co-authored a paper, 
Histopatbolo&ic Flndlnp Following 
Corneal Gluing with N-
Butylcyanoacrylate in 26 Patients. 
This is to be presented at the 
Association for Research in Vision and 
Ophthalmology in Sarasota, Fla., in 
May. This study looks at 
histopathologic changes in the corneal 
stroma after application of a tissue 
adhesive to the cornea during clinical 
trials. The clinical results of the study 
were previously reported by Dr. 
Leahey in Ophthalmology, Vol. 100, 
1993; however, this is the first time 
that a large number of clinical cases 
have been looked at histopatho-
logically. 
Definin& Value: Turning Softer 
Issues Into Hard Numbers, an article 
written by Donald L. Levick, M.D., 
pediatrician, appeared as the Guest 
Editorial in the February 1994 edition 
of The Physidan 's Advisory. 
Upcoming Semi1UlTS, Conferences and Meetings 
Regional Symposium Series V 
Update on Heart and Lung Surgery 
will be presented on Saturday, March 
26, from 7 a.m. to 12:45 p.m., in the 
Auditorium of Lehigh Valley Hospital, 
Cedar Crest & 1-78. 
Physicians, nurses, and other health 
care professionals interested in an 
update on heart and lung surgery will 
benefit from this program. 
At the completion of the program, 
participants should be able to: 
• describe cardiomyoplasty and its use 
in various patient populations 
• describe the new technique for 
artificial replacement of the aortic 
valve and arch, and 
• describe the indications for using 
thoracoscopic surgery as a treatment in 
pulmonary and mediastinal disease. 
Update: Management of Diabetes in 
Chlldren will be presented on 
Thursday, April21, from 1 to 4:30 
p.m., in the Auditorium of Lehigh 
Valley Hospital, Cedai Crest & 1-78. 
Physicians, family practitioners, 
nurses, and other health care 
professionals interested in the 
management of diabetes in children 
will benefit from this program. 
At the completion of the program, 
participants should be able to: 
• describe the outcomes associated 
with tight control of diabetes mellitus 
in children 
• discuss the state-of-the-art 
prevention, diagnosis, and treatment of 
renal complications in juvenile onset 
IDDM. 
For more information, please contact 
Human Resource Development at 
402-4609. 





Continued from Page 1 0 
Penn State Continuing 
Education 
Fetal Alcohol Syndrome/Fetal 
Alcohol Effects: Prevention, 
Intervention, and Diagnosis will be 
presented on Wednesday, April 6, at 
the Nittany Lion Inn, State College, 
Pa. 
Family practitioners, obstetricians/ 
gynecologists, and pediatricians will 
benefit from the program. 
For more information, call 
(717) 531-7965. 
Customer Service Excellence in the 
Business of Health Care will be 
presented on Wednesday, April20, 
from 8:30a.m. to 5 p.m., at the 
Holiday Inn East, Harrisburg, Pa. 
All healthcare employees having direct 
patient or public contact will benefit 
from this workshop. 
Participants should learn: 
• the basic skills of excellent customer 
relations service 
• critical communication skills for the 
public-contactpenwn 
• key winning service techniques 
• strategies for recognizing and 
dealing with different types of 
questions 
• methods for handling complaints and 
anger 
• a system for handling stressful 
disagreements 
• strategies for reaching agreement 
For more information, call 
(717) 531-6596. 
Otolaryngic Allergy and 
Immunology: The Basics and Beyond 
will be presented Friday, May 20 
through Wednesday, May 25, at the 
Sheraton Station Square, Pittsburgh, 
Pa. 
This course is for otolaryngologists or 
interested primary care physicians 
wishing to add allergy to their practice 
or to update their knowledge of current 
techniques. 
For more information, please call 
(717) 531-7965. 
Medical Grand Rounds 
H-Pylori will be presented by Robert 
Ganz, M.D., Clinical Instructor of 
Medicine, University of Minnesota, on 
Tuesday, March 15. 
Benip Prostatic Hypertrophy will be 
presented by Edward M. Mullin, Jr., 
M.D., urologist, on Tuesday, March 
22. 
Nousurgical Management of Patients 
With Lower Back Pain: The 
Noncutting Edge will be presented by 
Richard Bonfiglio, M.D., Bryn Mawr 
Rehabilitation Hospital, on Tuesday, 
March 29. 
The above Medical Grand Rounds will 
begin at noon in the Auditorium of 
Lehigh Valley Hospital, Cedar Crest & 
1-78. For more infonnation, contact 
the Department of Medicine at 
402-8200. 
Continued on Page 12 
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Department of Pediatrics 
Developmental Genetics Screening 
will be presented by Roger Ladda, 
M.D., Chief, Division of Genetics, 
Hershey Medical Center, on Friday, 
March 25. 
Update of HIV will be presented by 
Rick Rutstein, M.D., Medical 
Director, Special Immunology Clinic, 
Children's Hospital of Philadelphia, on 
Friday, April 8. 
Pediatric conferences are held at noon 
in the Auditorium of Lehigh Valley 
Hospital, 17th & Chew. For more 
information, contact Beverly 
Humphrey in the Department of 
Pediatrics at 402-2410. 
Psychiatric Grand Rounds 
Clinical and Research Advances in 
Multiple Personality will be presented 
by Marlene Steinberg, M.D., Associate 
Research Scientist in the Department of 
Psychiatry, Yale University School of 
Medicine, New Haven, Conn., on 
Thursday, March 17, from noon to 1 
p.m., in the Auditorium of Lehigh 
Valley Hospital, 17th & Chew. 
As lunch will be provided, pre-
registration is requested by calling the 
Department of Psychiatry at 402-2810. 
Babysitting Class Offered 
Would your babysitter know what to 
do if your child swallowed an object 
and was choking? Would he or she 
know who to call if a fire started in 
your kitchen? These and other 
questions will be answered during 
SuperSitter, a free babysitting class 
offered as a public service by Lehigh 
Valley Hospital. This program will be 
held on Saturday, April 30, from 8:45 
a.m. to noon, in the Auditorium of 
Lehigh Valley Hospital, 17th & Chew. 
SuperSitter is geared toward youths 11 
years and older who want information 
on becoming a knowledgeable 
babysitter. Speaking on various 
aspects of safety, emergencies, and 
first aid will be members of the 
Allentown Police and Fire departments 
and an educator from the Lehigh 
Valley Poison Center. Some helpful 
tips on general infant and toddler care, 
how to find babysitting jobs, and the 
proper way of communicating with 
employers will also be offered by 
employees of various hospital 
departments. 
Certificates and special SuperSitter 
notepads will be awarded to all those 
who attend the three-hour session. As 
space is limited to 100 participants, 
early registration is suggested. 
Deadline to register is April 22. For 
more information or to register, call 
WomanCare at 402-3800. 
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• For Sale or Lease --
Springhouse Professional Center, 
1575 Pond Road. Ideal for 
physician's office. 
Approximately 1 ,000 sq. ft. 
• For Sales or Lease -- Medical/ 
Professional three-story office 
building at 1730 Chew Street, 
Allentown. Excellent condition 
with recent renovations. 
Approximately 6,800 sq. ft. for 
single or multiple specialty 
practice. Includes long-term 
parking lease at Fairgrounds. 
Potential telephone and dictations 
systems. 
• For Sale-- Office building at 
Northeast comer of 19th and 
Turner Streets in Allentown. 
Upper level - 2,400 + sq. ft., 
large waiting room, two large 
consultation rooms, five exam 
rooms, etc. Lower level -
2,300 + sq. ft. Parking lot for 16 
cars. 
• For Lease -- Office to sublet on 
Monday, Tuesday, Thursday, and 
Friday. 950 sq. ft. Common 
waiting area. Lakeside Profess-
ional Building, Quakertown. 
• For Lease -- Monday time slot 
available in the medical office 
building on the campus of 
Gnaden Huetten Memorial 
Hospital in Lehighton. 
• For Lease -- Medical/profess-
ional office space located on 
Route 222 in Wescosville. Two 
1 ,000 sq. ft. offices available or 
combine to form larger suite. 
• For Lease -- Slots are currently 
available for the Brown Bag suite 
at Kutztown Professional Center. 
Ideal for satellite location. 
• For Lease -- Large, newly 
remodeled, completely furnished 
medical office space available for 
subleasing/time share at Cedar 
Crest Professional Park. Top of 
line telephone system. Transcrip-
tion and computer system with 
electronic billing available. 
• For Lease -- Medical office 
space located in Peachtree Office 
Plaza in Whitehall. One suite 
with 1 ,500 sq. ft. (unfinished -
allowance available), and one 
1 ,000 sq. ft. finished suite. 
• For Lease-- Specialty practice 
time-share space available in a 
comprehensive health care 
facility. Riverside Professional 
Center, 4019 Wynnewood Drive, 
Laurys Station. Half- or full-day 
slots immediately available. 
• For Lease -- Professional office 
space available in an established 
psychology and psychotherapy J 
practice at 45 North 13th Street, 
Allentown. Large, warm 
Victorian building in a relaxed 
atmosphere. Secretary and 
billing available and included in 
some leases. Furnished or 
unfurnished full offices and 
sublets available. Utilities 
included. 
For more information, contact 
Joe Pilla, Physician Relations 
Rep, at 402-9856. 
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WHO'S NEW 
The Who's New section of Medictrl Staff 
Progress Notes contains an update of new 
appointments, address changes, newly 
approved privileges, etc. Please remember 
that each department or unit is responsible 
for updating its directory, rolodexes, and 
approved privilege rosters. 
Medical Staff 
Appointments 
J. Stephen Long, MD 
Trexlertown Medical Center 
6802 Hamilton Blvd. 
Trexlertown, PA 18087 
(610) 395-1924 
Department of Family Practice 
Provisional Active 
Meera V. Pathare, MD 
Valley Medical Center 
Route 663 & Geryville Pike 
P.O. Box 216 
Pennsburg, PA 18073 
(610) 679-8071 
Department of Medicine 
Division of General Internal Medicine 
Provisional Courtesy 
Additional Privileges 
John J. Stasik, MD 
Department of Surgery 
Division of Colon & Rectal Surgery 
Active 
Intra-Rectal Ultrasound Privileges 
Change of Status 
John B. Longenhagen, MD 
Department of Medicine 
Division of General Internal Medicine 
From Courtesy to Emeritus Courtesy 
Martin D. Misenhimer, MD 
Department of Pediatrics 
Division of General Pediatrics 
From Active to Emeritus Active 
Carmine J. Pellosie, DO 
Department of Family Practice 
Division of Occupational Medicine 
from Provisional Courtesy to Provisional 
Active 
Cllfford G. Vernick, MD 
Department of Surgery 
Division of Orthopedic Surgery 
Section of Ortho Trauma 
From Active to Emeritus Active 
Brian D. Wilson, MD 
Department of Family Practice 
From Courtesy to Provisional Active 
Practice Changes 
Kevin J. Glancy, MD 
No longer associated with Surgical 
Associates of the Lehigh Valley, Inc. 
Practice Name Change 
The corporate name Robert Kiesel, MD, 
PC has changed to Fairgrounds Eye 
Associates, PC. The practice includes 
Robert Kiesel, MD, & Alan Leahey, MD 
Address Change 
Kevin J. Glancy, MD 
1210 S. Cedar Crest Blvd. 
Suite 3900 
Allentown, PA 18103 
(610) 402-8445 
Allied Health Professionals 
Resignation 
Donna Strain, MA 
Physician Extender 







P & T Highlights 
The following actions were 
taken at the February 14, 1994 
P & T Committee meeting. 
James A. Giardina, R.Ph., 
Director of Pharmacy 
FORMULARY ADDITIONS 
BREATHING EASIER ..... . 
Dornase Alfa (Pulmo:zyme, Genentech)-
is the newest biotechnology agent 
approved in 1993. Dornase Alfa is 
indicated in conjunction with standard 
therapies in the management of cystic 
fibrosis patients to reduce the frequency of 
respiratory infections requiring parenteral 
antibiotics and to improve pulmonary 
function. Dornase Alfa is recombinant 
DNase, a glycoprotein, and is thought to 
work through selective cleavage of DNA 
in purulent secretions in the airway. 
Dornase Alfa is given via certain 
nebulizers or compressors as an inhalation. 
It's onset of action is usually seen in 3 
days. -To be effective, Dornase alfa should 
be given chronically. The recommended 
dose is 2.5 mg daily. Some patients 
(study subset analysis suggests pts > 21 
years or with FVC > 85% of predicted) 
may benefit from twice daily inhalations. 
Patients with FVC < 40% of predicted 
showed no pulmonary function benefit in 
short term use from Dornase Alfa therapy. 
Safety & efficacy have not been 
demonstrated in pts < 5 years old. 
There are no well controlled studies in 
pregnant women, and excretion in breast 
milk is unknown. Dornase alfa is 
contraindicated in patients with known 
hypersensitivity to any of its ingredients, 
including its derivation source, Chinese 
Hamster Ovary cell products. The most 
common adverse events include voice 
alteration, pharyngitis, laryngitis, 
conjunctivitis, chest pain, and rash. In 
clinical trials, most reactions were 
transient, mild, and did not require dosing 
alterations. Few patients (3%) 
experienced reactions which required 
permanent discontinuation. While no 
formal drug interaction studies have been 
performed, it appears that Dornase alfa 
can be safely and effectively used in 
conjunction with standard cystic fibrosis 
therapies. It should not be mixed with 
other drugs in the same nebulizer. 
Dornase alfa inhalation solution must be 
refrigerated & protected from strong light. 
It should not be exposed to room 
temperatures for a total time of 24 hours. 
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Loratidine (CIIlritin, Schering) is a long 
acting antihistamine, classified as a 
selective peripheral H1 receptor 
antagonist. Loratidine possesses less 
potential for CNS effects than earlier 
generation antihistamines, and also appears 
to have less tendency for adverse cardiac 
(Torsades de Pointes) events and drug 
interactions than either Terfenadine 
(Seldane) or Astemizole (Hismanal). It is 
rapidly absorbed following oral 
administration and undergoes rapid first 
pass metabolism to an active metabolite. 
Onset of action occurs within 1 to 3 hours, 
reaching a peak in 8 to 12 hours and 
lasting longer than 24 hours. Patients with 
hepatic impairment have reduced 
clearance. Both Loratidine and it's 
metabolite are excreted in breast milk. 
Loratidine is given as a 10 mg tablet daily 
to patients over 12 years of age. 
Although peak concentrations are elevated 
in renal failure, elimination half lives 
REVERSING THE SWITCH ... 
Diltiiu.em CD (Cardizem CD, MMD) is 
one of the once daily formulations of this 
Calcium Channel Blocker. The Committee 
approved adding this formulation to the 
Formulary and reversing the substitution 
practice of dispensing Diltiazem SR when 
either Cardizem CD or Dilacor XR was 
ordered. Diltiazem CD comes as 120 mg, 
180 mg, 240 mg & 300 mg sustained · 
release capsules. Aside from the once 
daily dosing and the different strengths, all 
other prescribing information is the same 
as with the other Diltiazem formulations. 
appear similar to those in non renal 
impaired patients, therefore no dosage 
adjustment is recommended by the 
manufacturer in these patients. In patients 
with hepatic failure, the dose should be 
given every other day. Common adverse 
events include headache, somnolence, 
fatigue & dry mouth. Risks of adverse 
effects increase with increased dose (not 
recommended), in geriatric patients and in 
those with renal or hepatic impairment, 
even at usual doses. While no ECG or 
adverse effects were noted in limited 
studies with ketoconazole or 
erythromycin, caution should be used with 
these and any other agents known to 
impair hepatic metabolism. Loratidine 
costs about $1.30/day, which is 
comparable to Terfenadine & Astemizole, 
yet significantly more than 
Chlorpheniramine ($0.12/day). Given that 
Loratidine appears to offer several 
advantages over Astemizole, Loratidine 
was added and Astemizole was deleted 
from the formulary. 
As with many other sustained release 
formulations, these products should not be 
crushed. The Committee agreed to the 
following: 
- Add Diltiazem CD to the Formulary 
- Dispense the CD formulation for all 
twice daily SR orders and identical 
strength Dilacor XR orders 
- Dispense the SR formulation for non 
twice daily SR orders 
- Communicate these changes to the 
Prescriber via an Order "per P&T 





Finasteride (Proscar, Merck) & 
HydroxypropylmethylceUulose (HPMC) 
2% (Occucoat, Storz) had been added to 
this category in 1993 to allow for 
evaluation prior to consideration for 
formulary addition. Finasteride ruis had 
consistent use and was added to the 
formulary. Note was again made of the 
precaution relative to females of child 
bearing potential not touching the tablets. 
(Pharmacy dispenses each dose with a 
caution sticker). On the other hand, the 
Committee requested that the 
Ophthalmology Division review the role of 
HPMC together with Sodium 
Hyaluronidate (Healon) and Chondroitin & 
Sodium Hyaluronidate (Viscoat) prior to a 
decision on formulary status for this agent. 
DRUG USE EVALUATION (DUE) CORNER 
Target Antibiotics 
Overview - December costs were $110,478, which is 2% less than November. Average cost 
per gram was also less than November 93 as well as December 92. 
Ciprofloxacin - 20 patients receiving IV 
ciprofloxacin were reviewed in December. 
No cases of surgical prophylaxis were 
noted. 14 (70%) cases of empiric therapy 
were observed with the average length of 
therapy of 3 days. IV to PO conversion 
Ceftazidime - 48 patients receiving 
ceftazidime were reviewed in December. 
(Piperacillin therapy was chosen in 83 
cases during this month). 64.6% of the 
ceftazidime use was empiric with an 
average length of therapy of 4.1 days. 
Piperacillin conversion notes were non 
AmpiciUin/Sulbactam - 60 patients 
receiving ampicillinlsulbactam were 
reviewed in December. 17 (28.3%) of 
cases were being treated for mixed 
infections with therapy changed to oral as 
soon as feasible in the majority of cases. 
38 (63.3%) received amp/SB empirically 
memos were placed on 12 of 20 60%) 
charts. The remaining 8 cases were either 
non applicable for oral therapy or had their 
antibiotic regimen changed or D/C'd prior 
to review. Of the 12 notes placed only 2 
( 16.7%) were changed to oral therapy. 
applicable in all the ceftazidime 2 Gm 
cases due to allergy, piperacillin failure, or 
therapy discontinuation before our review. 
One pan sensitive PSAE UTI received I. V. 
ceftazidime therapy for 4 days before it 
was changed to oral ciprofloxacin. 
with an average LOT of 3.6 days. One 
surgical prophylaxis case is noted with 
48H of antibiotic therapy post vaginal 
hysterectomy. The approved amp/SB 
chart memos were begun mid-December. 
No data regarding their success is available 
as yet. 
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PATCHING CHRONIC PAIN ... 
Transdennal Fentanyl Usage Criteria 
The manufacturer recently included a 
boxed warning in the official labelling 
stating that serious or life threatening 
hypoventilation could occur with 
transdermal fentanyl (Duragesic, Janssen) 
and that it is contraindicated in the 
management of acute or post operative 
pain (including outpatient surgery), mild or 
intermittent pain manageable by lesser 
means, in doses exceeding 25 mcg/hr at 
initiation of opioid therapy, and in children 
less than 12 or patients under 18 weighing 
less than 50 kg except in an authorized 
investigational research setting. The 
Committee approved the following criteria 
for study of transdermal fentanyl usage: 
Justification Chronic pain (pain present 48 hours post op & expected to 
last 30 days) uncontrolled by lesser means, which requires 
continuous opioid use. 
Dosing (initial) 25 mcg/hr if naive to opioids; if receiving opioids, dosing is 
based on comparable total daily morphine use. 
Dosing (adjustment) After three days based on supplemental analgesics; subsequent 
adjustments should be made every six days. 
Contraindications Pre-existing pulmonary disease. 
Complications (presence) Occurrence of side effects together with management (if 
required). 
Outcome measure Documentation of pain relief. 
ERRATA, ERRATA 
In the last issue of P & T Highlights the 
cost of Liothyronine injection 60mcg was 
pt\21494.hi 
inadvertently stated at $1100/dose. The 







A.D. Rae-Grant, M.D., 
F.R.C.P.(C.) 
S. Lammers, Ph.d. 
) J. Vincent, M.D. 
· G. Brunst 
Issues In Medical Ethics 
Editorial: 
I n this second issue of"Issues ... " Dr.Stephen Lammers discusses Do-Not-Resuscitate orders, advance directives and the patient self determination act (PSDA). These timely and important issues are presendy the subject of a growing debate. Should 
cardiopulmonary resuscitation be applied to all patients unless specifically requested? 
Are we resuscitating people with no hope of recovery, squandering health care dollars 
on a 'futile' activity? Has the PSDA helped patients and families make their wishes 
known to hospitals and physicians in the event of a terminal or unrecoverable illness? 
Dr.Lammers guides us through these topics with thought provoking insights. Later in 
the spring the Ethics Committee will host a debate on Do-Not-Resuscitate orders. 
Look for announcements for this upcoming event. In the next issue: "Medical care for 
Jehovah's Witnesses." -AD. Rae-Grant 
The New "DNR" Debate 
Once again, cardiopulmonary resuscita-
tion (CPR) is the topic of contentious dis-
cussion in nursing and medicine. This very 
powerful and dramatically effective inter-
vention is at the center of what some are 
calling a "new'' debate. The occasion of 
the new debate is a worry that useless 
interventions are being tried and a related 
concern about the rising costs of medical 
care caused by these useless interventions. 
What are the issues? 
The first issue concerns the concept of 
futility in medical care. What is crucial 
here is how one defines "futility." For 
some commentators, a procedure is futile 
if it has less than a 15% chance of being 
effective. For other commentators, a pro-
cedure is futile only if the probability of 
effectiveness is 0%. These latter commen-
tators are focusing upon what has been 
called the "physiological" concept of futili-
ty. CPR is not futile under this latter defi-
nition of if it restores cardiac function to a 
patient in Persistent vegetative state (PVS) 
even though it will not restore conscious-
ness to the patient. 
Once one has determined how futility 
should be defined, and as yet there is no 
consensus in the literature, the next issue is 
whether CPR should automatically be 
given to patients? If the procedure is 
"futile", should it even be offered to 
patients? Is there any need to involve 
patients in a discussion of a therapy which 
cannot assist them? 
If we extend the analysis however, the 
issue of futility and CPR becomes even 
more complex. What happens if we take 
into account the patient's conception of 
futility, so that a patient might think CPR 
would be futile if it were unlikely to 
restore the patient to a level of functioning 
desired by the patient? Thus we could 
have a siruation in which CPR might not 
Continued on Page 2 
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be physiologically "futile" but would be 
"futile" in terms of the outcome desired by 
the patient and projected by the physician. 
A recent paper Gecker and Schneider-
man, 1993) has suggested that a physiolog-
ical definition of futility (a procedure is 
"futile" if and only if the probability of 
benefit is 0%) might set too high a stan-
dard but that there is a way for medical 
professionals to set a "patient centered" 
standard. In contrast to the physiological 
standard, physicians would be allowed to 
withdraw treatments, including CPR, not 
only when the probability of benefit is 0%, 
but when the quality of benefit falls below 
a certain minimal standard. One way to 
judge this is to ask whether the proposed 
treatment benefits only a failing organ or 
benefits the patient. In cases where there is 
a patient in a persistent vegetative state, 
CPR does not, in the opinion of these 
authors, benefit the patient. What remains 
in dispute is the process of consultation 
the physician would have to go through in 
order to do this. 
This new debate also has made it clear 
that there are some issues which were not 
settled in previous discussions of CPR and 
DNR orders. For some physicians and 
nurses, a DNR order is compatible with 
aggressive care; for others, a DNR order is 
a signal that one has "given up" on trying 
to cure the patient and one has begun the 
process of care that will lead to the patien-
t's death. In fact, the ethical stan~ard here 
is clear. DNR orders are compatible with 
aggressive care and should not be inter-
preted, by themselves, as evidence that 
other treatments should be withdrawn. Of 
course, a DNR order may be part of a care 
plan for a patient that will include "corn-
fort measures only"' but there is no neces-
sary connection between DNR orders and 
comfort care. 
The new debate has also made it clear 
once again that different physicians have 
soikingly different understandings of what 
is being withheld if a DNR order is writ-
ten. For some, it means all attempts at 
resuscitation; for others, it means only 
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those resuscitative measures supported by 
a code team. In this hospital, DNR indi-
cates that the hospital code team will not 
be called in the event of a cardiac, pul-
monary or cardiopulmonary arrest. Fur-
ther, DNR also means that intubation and 
ventilation will not be initiated, there will 
be no closed cardiac massage, and no 
emergency medications will be given. 
Perhaps the most interesting proposal 
thus far questions whether CPR should 
have the status which it has in modern 
medicine. DNR orders are quite unusual 
in one sense, in that the usual hospital pro-
tocol is that whatever is going to be done 
must be ordered by a responsible party. 
There are always emergency exceptions to 
matters but the norm is that orders must 
be given before care is to be rendered. 
This is not true of CPR. It is done without 
an order and is withheld only if an order to 
withhold is given. CPR has become so 
much a part of the functioning of a mod-
ern hospital that we rarely give this a sec-
ond thought. The point here is not that 
this is necessarily irrational. If nurses had 
to wait for orders in many situations, the 
patient that could have been helped will 
have died. The point is that CPR is differ-
ent and the difference should be noted. 
Indeed, in the literature on nursing 
homes, one of the proposals is that CPR 
not be the norm, but should be given only 
if there is a physician's order that CPR is 
appropriate for this particular patient. The 
norm would be that DNR would be stan-
dard for all nursing home residents and 
CPR would be given only if it was directed. 
I am not taking a position here on this 
proposal, but the existence of the proposal 
does indicate that there is some attention 
to the status of CPR. The issue is being 
raised about classes of cases where the 
norm would not be "DO CPR!!" but the 
norm would be, "In cases like this one, we 
do CPR only if it is ordered". What sorts 
of cases these might be bring us back to 
the first discussion above. 




For example, there are cases in which 
CPR is not known to have any benefit to a 
patient if benefit is measured as "being dis-
charged alive". When such cases arise, the 
question is, should the standard of care be, 
"DO CPR!"? Perhaps the standard should 
be, "DO CPR ONLY IF IT IS 
ORDERED!" Patients could and should 
still be approached, so the argument goes, 
but the information that would be given 
would include the prognosis of death even 
if they survived CPR. In such a circum-
stance, the question, "Do you want us to 
do. everything?" is entirely inappropriate. 
Better here, and elsewhere, is the follow-
ing: "How do you want us to care for you? 
Let me tell you what we might do and 
what are the probable outcomes. Then let 
us discuss what you would like done". 
All this will not be easy, of course. In 
part it will not be easy because physicians 
may fear not offering and not doing every-
thing for patients, when "everything" is 
defined and described as high technology 
interventions. In part it is because we have 
radically undercut physician moral author-
ity in our society so that the physician 
might discuss with us how we might be 
appropriately cared for, instead of being 
only technologically assisted. We have 
confused "medical care" with "technologi-
cal assistance". Nor does refusal of techno-
logical assistance mean, "Doing nothing''. 
It may include all sorts of comfort care 
measures. 
In part it is difficult because Americans 
continue to perpetuate a death denying 
attitude which makes it difficult to discuss 
these matters. Thus they submit them-
selves to interventions such as CPR 
because they are unwilling to admit that 
there is a "time to die". 
It has been suggested that the new 
DNR debate began for the wrong reasons, 
that it might be driven by worries about 
the cost of health care. In truth, this 
charge may be true. But whatever the rea-
son for which it began, it offers the oppor-
tunity to be clearer about the limits of 
medical care and what is appropriate when 
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the limits on one kind of care are reached 
and another kind of care should begin. As 
confusing and as contentious as the debate 
might be, in that aspect at least, it is an 
opportunity for physicians and nurses to 
have conversations with their patients 
about what is important to them, and 
about the limits of the practices of nursing 
and medicine. The debate also makes it 
clear that values are an integral part of med-
ical practice, and that any choices which 
one makes on this issue involves values. 
What could help is if we knew more 
about CPR in particular contexts, so that 
physicians and nurses could better advise 
patients. Perhaps the next step in our own 
DNR debate would be to find out what we 
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PSDA And Advance Directives: 
"What Have We Leam.ed After Two Years? 
Over two years ago, hospitals and other 
health care providers were required to ask 
whether their patients had advance direc-
tives and to provide information about 
advance directives if the patients desired 
that information. The Federal legislation 
which mandates this process is called the 
Patient Self Determination Act (PSDA) 
and the advance directives usually dis-
cussed under this legislation include living 
wills and durable power of attorney for 
healthcare documents. In theory, of 
course, any written instruction could be an 
"advance directive." Thus organ donation 
documents and patient signed DNR 
orders might fall into this category. For 
purposes of the discussion here, we will 
focus only upon living wills and durable 
power of attorney for healthcare documents. 
The hope was, of course, that by asking 
patients whether they had such docu-
ments, and offering them information 
about advance directives, more patients 
would complete such documents and this 
would give patients more control over 
their medical care. In addition, some per-
sons hoped that more patients would 
choose less medical care at the end of their 
lives and health care expenditures would 
slightly decrease. 
Advance directives are now the subject 
of much attention in the medical litera-
ture. Investigators are curious about 
whether they are in fact used and, if they 
are used, under what circumstances. They 
are investigating what forms of advance 
directives are more helpful and which less 
helpful. The results of these investigations 
are interesting. They give us a look at the 
limits of centralized intervention in med-
ical care and they also tell us a lot about the 
ethos of medicine today. What do I mean? 
It is clear that advance directives are not 
being used as often as the proponents of 
them wished them to be. 
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For example, patients are too often 
writing advance directives right at the end 
of life. The reasons for this are unclear but 
what is clear is that patients should formu-
late advance directives much earlier in 
their lives if they are to be helpful to 
physicians, nurses, and family members. 
Investigators have learned that patients 
desire discussions about advance directives 
more than physicians desire to discuss the 
subject with their patients. Investigators 
learned that patients are more likely to 
develop useful advance directives if they 
participate in an educational process which 
includes more than one educational event. 
Advance directives which give patients sce-
narios to which they respond rather than 
statements to which they assent or dis-
agree are more helpful, both to physicians 
and patients. 
One of the consistent findings in study 
after study is that surrogates are very often 
at odds with the persons for whom they 
are supposed to be speaking. It is not sim-
ply that surrogates often do not really 
know what the person wanted; they often 
straightforwardly disagree and do not wish 
for the patient what the patient wishes for 
her or himself. This finding makes it more 
important than ever to discover why sur-
rogates are deciding what they decide in 
particular cases. Are they following the 
patients wishes or are they substituting 
their own wishes for the judgment of the 
patient? 
All of the above means that those of us 
who thought that PSDA would bring in a 
new day were mistaken. Now what must 
be done is to attend to the issues raised by 
the implementation ofPSDA so that bet-
ter care can be given to patients. 
In such a situation, what would seem 
like sensible advice to nurses and physi-
cians who have to care for patients? The 
Continued on Page 5 
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first finding that appears to be consistent is 
that physicians ought to be more forth-
coming in discussing with patients their 
wishes at the end of life. It appears that 
patients are much more willing to have 
these discussions than physicians believe 
and are less frightened by discussions of 
death than is widely believed in the med-
ical community. (fhis correlates well with 
an old social science finding that incoming 
medical students feared death more than 
the general population.) ~ving these dis-
cussions leads to more clarity about what 
patients desire, what are the limits upon 
treattnent which they wish to have imple-
mented in their case, and who they wish to 
speak for them. One study argues that the 
first patient visit is the time to begin. 
Having the discussions, of course, is 
only the beginning. Physicians and nurses 
should realize that they must be careful 
with their use of language, since that will 
sway patients. It is not that physicians do 
not have a role here; that role must be 
undertaken responsibly. Secondly, patients 
will vacillate on what they wish to be done. 
Patients will display here the same uncer-
tainties they display about other aspects of 
their medical care. 
Part of what is being considered here is 
a new direction in medical ethics, which 
some are calling "preventive ethics." This 
new direction grows out of the common-
place obsetvation that to leave a question 
unanswered often causes greater difficulty 
later when the primary decision maker, the 
patient, is no longer able to answer the 
question. If the patient had been sensitive-
ly and forthrightly approached, there 
would be a much better chance to know 
what the patient would have wanted. 
Assuming that the patient's wishes did not 
ask the physician and the nurses to violate 
the law or professional codes, the patient's 
wishes could be followed. In this sense, 
advance directives are a form of preventive 
ethics. They allow all of us who will be 
patients an opportunity to reflect on what 
we would like done medically as our lives 
come to their end and to indicate who 
5 
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Advance Directives And PSDA 
The following information sheet was 
developed by the Ethics Committee. It is 
our hope that this will help with the most 
asked questions about Advance Directives 
andPSDA. 
1. What does PSDA mean? PSDA 
stands for the "Patient Self Determination 
Act." It is a shorthand way of referring to 
Federal legislation which applies to all 
providers of healthcare. 
2. To whom does PSDA apply? The 
Patient Self Determination Act applies to 
any adult patient admitted to the hospital. 
3. What must the hospital do? The 
hospital has three immediate obligations 
under the law. First, the hospital must 
advise the person that they have the right 
to make an Advance Directive. Second, 
the hospital must ask whether the person 
has an Advance Directive. Third, if the 
person does not have an Advance Direc-
tive, the hospital must inquire if they wish 
more information about advance directives 
and, most importandy, the hospital must 
try to supply that information. 
4. Who does these things at LVH? 
At Admission, all patients will be provided 
with written information. Nursing staff are 
responsible for asking if the patient has an 
advance directive and, if the patient has 
one, for a copy for the chart. Nursing also 
asks whether the patient desires more 
information. 
5. What does Nursing do when it 
discovers that a patient wants more 
infonnation? Nursing should contact the 
PSDA team. They are responsible for see-
ing the patient and assisting the patient in 
any way appropriate. The PSDA team 
·consists of patient representatives, chap-
lains, and clinical social workers. 
6. What is an Advance Directive? 
An Advance Directive is most often a doc-
ument which either 1) indicates the 
patient's wishes about medical treatment 
when the patient can no longer speak for 
6 
her or himself (Living Will) and/or 2) 
indicates who may speak on behalf of the 
patient when the patient can no longer 
speak for her or himself (Durable Power 
of Attorney for Healthcare Decisions). 
However, a patient's statement to a physi-
cian about how s/he wishes to be treated, 
properly documented in the chart, will 
also serve as an Advance Directive. 
7. Does that mean an Advance 
Directive does not apply to a compe-
tent patient? That's right! Advance 
Directives only go into action when a 
patient cannot speak for her or himself; if 
the patient can communicate, the patient 
should be addressed. To put this another 
way: Advance Directives do not determine 
medical care for a competent patient. 
8. Where would I find a patient's 
Advance Directive? A patient's Advance 
Directive should be put in the chart, in 
front of the Inpatient Face Sheet. IT there 
is a DNR order, the Advance Directive 
should be placed immediately behind it. 
9. Are Advance Directives legal in 
Pennsylvania? In April, 1992, Pennsylva-
nia passed legislation making Living Wills 
and Durable Power of Attorney for 
Healthcare legal documents. 
10. 'Who can cancel an Advance 
Directive? An Advance Directive may be 
cancelled at any time by a competent 
patient. 
11. Does an Advance Directive 
means that a patient should be a 
DNR? Not at all! Patients may wish to 
have DNR status but the existence of an 
Advance Directive implies nothing about 
code status. 
12. 'Where can I obtain answers to 
questions which may arise regarding 
Advance.Directives? The patient repre-
sentatives and the Legal Affuirs depart-





NEWSLETTER HEALTH NETWORK LABORATORIES 
LABORATORY DIAGNOSIS OF MYOCARDIAL INFARCTION 
Myocardial infarction is a medical emergency requiring careful 
management of the patient. In excess of SO% of all deaths associated 
with a MI occur within the first 2 hours after the onset of symptoms. 
Myocardial infarction is due to the reduction of blood flow {ischemia-
-energy deficit) which leads to cell death. With cell death comes 
increased permeability of the plasma membranes releasing three types 
of cellular components: ions {e.g., potassium), metabolites {e.g. 
lactate) and macromolecules {e.g. enzymes). All cellular components 
are measurable. However, from a laboratory position, the cytoplasmic 
enzymes are preferred for the following reasons: 
1) The are readily released from the cell. 
2) They have a finite half life with concentrations amiable to 
be measured. 
3) They are easily measured employing "routine" laboratory 
techniques with results reportable within 1-2 hours. 
Creatine kinase {CK) has been identified as the enzyme of choice. Its 
activity in tissue is highest in skeletal muscle followed by cardiac 
muscle, brain, intestine, kidney and lung. There are two types of CK 
monomers namely muscle {M) and brain {B) . However CK actually exists 
as a dimmer and there are 3 ways to combine 2 monomers: MM, MB, BB 
known as CK isoenzymes. Skeletal muscle cytoplasmic CK isoenzyme 
composition is 98% MM and 2% MB followed by heart at 70% MM and 30% MB 
and finally brain which is 100% BB. The other organs are largely BB 
with a small amount of MM with almost no MB. 
With this background, laboratories utilized the production of CKMB 
isoenzyme and total CK activity for the differential diagnosis of a 
myocardial infarction from skeletal muscle or other organ damage. 
Following a MI the total CK activity and CKMB isoenzyme will peak 
{rise and fall) within a 24 hour period. This peaking can be used as 
one of three criteria for the diagnosis of a MI. The other two 
criteria are changes in EKG and clinical presentation of the patient. 
None of these criteria is 100% sensitive for the diagnosis of a MI but 
serial cardiac isoenzymes are 95%, followed by EKG at 70% and finally 
clinical presentation such as chest pain at 40%. 
For many years we have provided MI profiles that were comprised of 
total CK & CK isoenzymes and total LD and LD isoenzymes ordered as a 
battery of 3 specimens obtained upon admission, 6-12 hours later and 
finally 24-36 hours post admission. These were offered on a routine 
basis, not STAT, and exhibited excellent predictive value. 
In response to the changing requirements in delivery of healthcare 
services, the laboratory changed its methodology for MI profiles to 
include total CK, a very sensitive mass molecule CK-MB measurement and 
a specific LDl activity measurement. These tests are offered STAT and 
the entire profile is completed within a 16-24 period. These changes 




In considering a change of methodology for the laboratory diagnosis o_ 
a MI, the following strategy was developed as guidelines for selection 
and subsequent monitoring of this new testing protocol. 
1) Use complementary markers in the cardiac panel 
a. Total CK, MCKMB and LD1. 
2) Select optimal cutoff values for our population 
a. Comparative studies were completed. 
3) Interpretation should consider test combinations not 
individual results. 
a. Reference ranges on the reports reflect this concept. 
4) Continuation with sequential sampling. 
a. The ordering of an MI profile of 3 specimens should be 
transparent to the physician. 
5) Determine the prevalence of MI in the population. 
a. Low prevalence results in low specificity. 
6) Use Total CK cutoff to indicate CKMB testing. 
a. This criteria has not been instituted at this time. 
After experience with the new testing, it will be 
proposed that we do not do CKMB testing on patients 
with total CK less than some number (for example 
75 U/L) . It is this group of patients that contribute 
the most to the false positive result. 





10 - 230 u/L 
< 5.0 ng/ml 
< 4.0% 
25 - 70 u/L 
The relative index is obtained by dividing the MCKMB value by the 
total CK. It is particularly useful to help differentiate between a 
MI and skeletal muscle trauma. It may not be as useful for those 
patients who exhibit a low normal total CK. It is mandatory, in using 
these laboratory values to help in diagnosing a MI, to look at the 
serial pattern presentation of the 3 specimens. Depending on the 
patients age and sex none of the measured parameters may be above the 
reference range. The elderly, especially females, have lost muscle 
mass so that their laboratory values may start very low and never rise 
into the abnormal range. Even in these cases the peaking of MCKMB 
with increasing LD1, is expected for the diagnosis of MI. 
However, the serial presentation of peaking of MCKMB with increasing 
LDl, may still be consistent with the diagnosis of MI. 
) 
It has been brought to the laboratories attention that a number of 
patients present with normal to low normal total CK, a slightly 
elevated CKMB with an abnormal relative index (RI) and a low LDl. 
This presentation does not change for the 3 specimens of the MI 
profile. Examples of patient presentations with diagnosis are given 
below. 




lex l MCltMB _l RI I LDl Cit I MCIDIB I RI I LDl Cit I MCltMB I RI I LDl 
ISCHBMIC HEART DISEASE WITH CRP 
I 88 I 7.1 I 8.1 I 57 113 I 7.6 I 6.7 I 49 125 I 8.1 1 6.5 l 59 
UNSTABLE ANGINA WITH CORONARY ARTERY DISEASE 
I 115 I 10.6 I 9.2 I 30 II 119 I 12.1 I 10.1 I 48 100 I 8.7 I 8. 7 I 67 
ACUTE ANTERIOR WALL MI 
I 178 114.5 I 8.H I 56 201 I 18.6 18.n I 61 145 I 12.8 I 8. n I 73 
Although the MCKMB is elevated in the first two profiles they do not 
exhibit the standard increase-decrease of the total CK and MCKMB. The 
relative index is elevated because the total CK is low and the MCKMB 
is slightly elevated. These results are usually consistent with a 
cardiomyopathy, ischemic heart disease due to coronary insufficiency, 
unstable angina, CHF or some combination of the above. It is often 
difficult to differentiate unstable angina from minimum cardiac damage 
with these laboratory tests. Some laboratories designate a 9X§Y area 
for MCKMB range of 5-8 ng/ml and LDl 70-120 U/L but we have chosen not 
to institute this approach at this time. 
We will continue to monitor the MI profile results with the following 
objectives. First, do our reference ranges require adjustment? 
Secondly, can we increase the diagnostic predictability of the profile 
by establishing a cutoff point below which we will not do MCKMB and 
LDl measurements? Thirdly, does the LDl measurement help in the 
diagnosis of a MI? If it is not clinically useful in the 
identification of a prior MI, (occurring > 12 hours prior to 
treatment) then should it be offered especially in these times of cost 
containment? 
John J. Shane, MD 
Chairman, Pathology 
Editor 
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